Last reviewed · How we verify

NCT05609916

CBT Augmentation to Promote Medication Discontinuation in Pediatric OCD

Recruiting now NA Last updated 20 July 2025
What this trial tests

NA trial testing Cognitive Behavioral Therapy in Cognitive Behavioral Therapy in 200 participants. Currently enrolling.

Timeline
30 November 2022
Primary endpoint
30 December 2026
30 August 2027

Quick facts

Lead sponsorBaylor College of Medicine
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingquadruple
Primary purposetreatment
Enrollment200
Start date30 November 2022
Primary completion30 December 2026
Estimated completion30 August 2027
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Baylor College of Medicine

Who can join

Adults 7 to 17, any sex, with Cognitive Behavioral Therapy or Obsessive-Compulsive Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to examine whether youth with OCD who benefit from CBT augmentation to SRI can discontinue their medication without relapse over 24 weeks.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Cognitive Behavioral Therapy

Trials testing the same drug.

Other recruiting trials for Cognitive Behavioral Therapy

Currently open trials in the same condition.

Other Baylor College of Medicine trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05609916.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing